FIG 3.

PPIase activity of CypA is required for chondrogenic differentiation. (A to D) ATDC5 cells were treated with DMSO (as a control) and PPIase inhibitor, CSA or SFA, at the indicated concentrations in chondrogenic differentiation medium for 14 days, and the relative mRNA expression levels of Sox9 (A), Col2α1 (B), Col10α1 (C), and Runx2 (D) were quantitated by qRT-PCR. Mean values (n = 3) and standard deviations are shown. (E) NF-κB luciferase assay in ATDC5 cells treated with DMSO, CSA, or SFA for 24 h. Luciferase reporter plasmids, pGL4 nf-κb-Luc with the consensus NF-κB binding sequence GGGACTTTCC and its mutant with a mutated sequence (CTCACTTTCC), were used. *, P < 0.05, and **, P < 0.01 compared to the DMSO treatment group. The data are shown as means and SD of three experiments.